Interview: Dr. Amr Morsy – CEO, Rameda, Egypt
Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5…
Rameda aims to become the most valuable emerging pharmaceutical company in Egypt. The company’s mission is to provide customers with quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements.
Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region.
Owners hired V-Konsult of Germany to create a state-of-the art design, and British Carter Construction company was contracted to build the Rameda’s facilities.
In 1999, Rameda entered into an agreement with Alcon to manufacture – under license – their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda.
In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry.
To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team.
Contact
Cairo Scientific Office
8 Geziret El Arab Street (23rd Floor), Mohandessin, Giza, Egypt
+(202) 376 130 46 / 58 / 74
+(202) 376 130 18
Factory
Second Industrial Zone, plot number 5
Sixth of October, Egypt
+( 202) 383 31887 – 383 31848
+(202) 383 31849
Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5…
Concerted efforts are, at last, being made to redraw the rulebook and tidy up a local regulatory landscape long renowned for its torpor, dysfunction and ineffectuality. The Egyptian pharmaceutical market…
In an exclusive discussion with Focus Reports, Egyptian Minister of Health, Dr. Ahmed El Din Rady sets out his blueprint for improving the nation’s welfare and securing positive public health…
Ten years after his first interview with Focus Reports, Wafik Bardissi discusses Minapharm’s position as the leading biosimilar manufacturer in the Middle East. Has Egypt taken steps to incentivize the development or registration…
Fresenius Kabi’s general manager for the MENA region discusses evolving attitudes towards clinical nutrition for critically ill patients and Egypt’s positioning as a knowledge center and source of medical professionals…
Former Egyptian Minister of Health Adel Adawy discusses the reforms needed in the Egyptian healthcare system and the progress made in the fight against HCV over the last two years.…
Japanese company Otsuka envisioned Egypt as a hub for its Middle East and African operations as early as 1995. The president of the local subsidiary discusses the current activities of…
Oncology already represents the second largest portion of Egypt’s public healthcare budget, and despite limited public funding, demand for and acceptance of innovation is high, according to Roche’s regional general…
While growth forecasts for the MENA region remain high, falling oil prices and political instability are creating significant government budgetary challenges for the industry to adapt to. Janssen’s area managing…
“My primary concern is not the current economic situation, but rather the fact that there does not appear to be a clear vision for how Egypt can overcome these challenges…
The founder of the Middle East’s largest pharmaceutical company, EIPICO, discusses the evolution of the Egyptian pharmaceutical industry over the last 50 years, and his hopes for the industry over…
Eva Pharma is one of the fastest growing pharmaceutical companies in the MENA region, and CEO Riad Armanious is aiming to take the company from the 21st ranked generic company…
After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses…
See our Cookie Privacy Policy Here
